GlassScriptPhysician profile
Humera Ahmed
NPI 1326268400
$2,017.69
in general payments reported to CMS, 2019-2025
27 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $760 · 2020: $83.80 · 2021: $32.65 · 2022: $316 · 2023: $248 · 2024: $233 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $320.59 | 2019-2024 | Breztri |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.13 | 2019-2022 | |
| Amgen INC. | $197.60 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Itamar Medical INC | $172.98 | 2022-2023 | Watchpatone |
| Novo Nordisk INC | $148.37 | 2019-2025 | Wegovy |
| Abbvie INC. | $136.18 | 2019-2025 | Ubrelvy, Linzess |
| Genzyme Corporation | $125.00 | 2025 | |
| Lilly USA, LLC | $88.49 | 2019-2025 | Mounjaro, Kisunla, Jardiance |
| Sanofi-Aventis U.S. LLC | $79.03 | 2019-2025 | |
| Glaxosmithkline, LLC. | $62.06 | 2019-2023 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.57 | 2024-2025 | Xifaxan, Trulance |
| Pfizer INC. | $44.62 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.10 | 2019-2023 | Trintellix |
| Exact Sciences Corporation | $40.24 | 2025 | The Cologuard Plus Collection Kit |
| Cleerly, INC. | $39.81 | 2024 | Cleerly Labs |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $36.55 | 2025 | |
| Genentech USA, INC. | $32.86 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.25 | 2021-2023 | |
| Radius Health, INC. | $31.23 | 2019 | |
| Lundbeck LLC | $27.01 | 2025 | Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.40 | 2022 | |
| Currax Pharmaceuticals LLC | $15.57 | 2024 | Contrave |
| Astellas Pharma US INC | $15.24 | 2023 | Veozah |
| Linus Health, INC. | $14.82 | 2023 | |
| Endomagnetics LTD | $13.37 | 2024 | Magtrace, Magseed |
| Ge Healthcare | $12.87 | 2019 | |
| Merck Sharp & Dohme LLC | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humera Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.